Results 71 to 80 of about 7,099 (210)

P99 Renal and bone safety of tenofovir alafenamide vs tenofovir disoproxil fumarate [PDF]

Sexually Transmitted Infections, 2015
Background Off-target renal and bone side effects may occur with tenofovir disoproxil fumarate (TDF) use. Compared with TDF, tenofovir alafenamide (TAF) results in significantly reduced plasma tenofovir (TFV) and may have less renal and bone toxicity.
Frank Post, Paul Sax, Michael Saag, Michael Yin, Shinichi Oka, Ellen Koenig, Benoit Trottier, Jaime Andrade, Huyen Cao, Marshall Fordyce   +9 more
openaire   +1 more source

Hepatitis B Surface Antigen Loss and Improved Clinical Outcomes in US Individuals With Chronic Hepatitis B Virus Infection

Journal of Viral Hepatitis, Volume 33, Issue 6, June 2026.
ABSTRACT Hepatitis B surface antigen (HBsAg) loss is associated with improved clinical outcomes in patients with chronic hepatitis B virus (HBV) infection based on studies predominantly in Asian populations. We assessed real‐world associations between HBsAg loss and long‐term clinical outcomes in a diverse US population with chronic HBV infection. This
Myriam Drysdale, Rose Chang, Shuang Wang, Anna Coutinho, Vera Gielen, Theo Man, Rui Song, Mei Sheng Duh, Mandana Khalili, Dickens Theodore   +9 more
wiley   +1 more source

Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles [PDF]

Clinical and Molecular Hepatology, 2022
Hung-Yao Lin, Tai-Chung Tseng
doaj   +1 more source

Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service

AIDS Research and Therapy, 2019
Background Tenofovir disoproxil fumarate (TDF) is widely used in the management of HIV-infection, but has been associated with renal impairment in a small proportion of patients.
Dane Turner, Douglas Drak, Catherine C. O’Connor, David J. Templeton, David M. Gracey   +4 more
doaj   +1 more source

Osteopenia in a young man associated with the use of tenofovir disoproxil fumarate

Clinical Case Reports, 2022
Tenofovir disoproxil fumarate is a recommended first‐line therapy for patients with chronic hepatitis B, although the frequent Tenofovir disoproxil fumarate related adverse drug reactions are nephrotoxicity and bone toxicity.
Chunmei Li, Hui Li, Ming Gong, Jia Wei
doaj   +1 more source

Low-level viremia in nucleoside analog-treated chronic hepatitis B patients

Chinese Medical Journal, 2021
. Low-level viremia (LLV) was defined as persistent or intermittent episodes of detectable hepatitis B virus (HBV) DNA (
Qian Zhang, Da-Chuan Cai, Peng Hu, Hong Ren, Peng Lyu   +4 more
doaj   +1 more source

Advancing Maternal Health with Long‐Acting Therapeutics: Priorities, Efficacy and Safety Considerations, and Emerging Technologies

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1179-1194, May 2026.
Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott, Sharon Nachman, Ethel D. Weld, Rachel Daley, Shakir Atoyebi, Robert Bies, Catriona Waitt, Adeniyi Olagunju   +7 more
wiley   +1 more source

Accelerating Generic Long‐Acting Antiretrovirals for Global HIV Treatment: Workshop Findings and a Roadmap to Access

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1195-1204, May 2026.
The global HIV response aims for widespread availability of affordable, quality‐assured long‐acting antiretroviral (LA ARV) drugs to achieve sustained epidemic control, particularly in low‐ and middle‐income countries. This report summarizes key discussion points, findings, and outcomes from an international workshop on generic LA ARVs, held in ...
Usman Arshad, Lobna Gaayeb, Henry Pertinez, Rajith K. R. Rajoli, Melynda Watkins, Parag Nimbolkar, Simone Perazzolo, Bharat Pagi, Annemarie Wensing, Saye Khoo, Marta Boffito, René Holm, Zack Panos, Imelda Mahaka, Francois Venter, Benny Kottiri, Keith W. Crawford, Rodney J. Y. Ho, Polly Clayden, Paul Domanico, Kimberly Struble, Andrew Owen, Charles Flexner   +22 more
wiley   +1 more source

Evaluation of Relative Bioavailability and Food Effect of a Fixed‐Dose Combination Tablet of Islatravir and Lenacapavir

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Long‐acting oral HIV‐1 treatments can potentially reduce pill burden, treatment fatigue, suboptimal adherence, and treatment failure. A combination of islatravir, a nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a capsid inhibitor, is being investigated as a weekly oral HIV‐1 treatment.
Jing Niu, Haeyoung Zhang, John Ling, Sharline Madera, Nerissa Kwok, Steve West, Diane Longo, Gillian Gillespie, Cyril Llamoso, Dhananjay D. Marathe   +9 more
wiley   +1 more source

Evolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: From treatment to prevention [PDF]

, 2013
The HIV epidemic continues unabated, with no highly effective vaccine and no cure. Each new infection has significant economic, social and human costs and prevention efforts are now as great a priority as global antiretroviral therapy (ART) scale up ...
A Bedri, A Calmy, A Coovadia, A Coovadia, A De Luca, A Hill, A Kunz, A Moorthy, A Moorthy, A Shibata, A Zolopa, AN Phillips, AY Liu, BE Nichols, BE Nichols, BG Brenner, BR Yehia, C Laurent, C Pretorius, C Unge, C Unge, C Zeh, CA Boucher, CB Hurt, CJ Hoffmann, CL Townsend, CS Chasela, D Descamps, D Frentz, D Frentz, D Persaud, DA van de Vijver, DA van de Vijver, DADS Group, DAMC Van de vijver, David A M C Van de Vijver, DC Vissers, DE Bennett, DJ McColl, E Arrive, E Bendavid, E Mills, EM Connor, ER Cooper, ES Daar, F Doualla-Bell, F Tanser, F van Leth, F van Leth, FA Frankel, FDA, FJ Palella Jr, G Jourdain, G Jourdain, GL Melikian, GN Nikolenko, H Sunpath, HM Coovadia, I de Vincenzi, I Thior, J Bor, J Fogel, J Marrazzo, J Mermin, J Mermin, J Ren, J Vercauteren, JA Hontelez, JA McIntyre, JB Nachega, JE Gallant, JE Gallant, JM Baeten, JM Baeten, JM Fogel, JM Whitcomb, JO Kahn, Joint United Nations Programme on HIV/AIDS (UNAIDS), JW Eaton, KA Delviks-Frankenberry, KN Althoff, L Ryom, L Van Damme, L Wittkop, LA Guay, M Lallemant, M Mirochnick, MA Fischl, MA Thompson, MA Wainberg, Mark A Wainberg, MC Hosseinipour, MC Thigpen, MD Miller, MS Cohen, N Ford, N Shaffer, N Sood, NA Martinson, NA Wade, NE Mackie, NI Kumwenda, P Mugyenyi, PR Meyer, Q Abdool Karim, R Granich, R Gupta, R Kaplan, Ravindra K Gupta, RE Barth, RF Schinazi, RF Schinazi, RK Gupta, RK Gupta, RL Hamers, RL Hamers, RL Shapiro, RM Granich, RM Grant, RM Gulick, RM Mainardes, RS Veazey, S Lockman, S Loubser, S Rosen, S Staszewski, S Staszewski, S Sungkanuparph, S Yerly, SH Eshleman, SH Yap, Sheetal Manicklal, SL Spruance, T Flys, U CHIC, UL Abbas, UM Parikh, UNAIDS, UNAIDS, V Cambiano, V von Wyl, VD Lima, VS Gill, WHO, WHO, Z Shubber   +145 more
core   +4 more sources